Zobrazeno 1 - 10
of 99
pro vyhledávání: '"Pirinixic Acid"'
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-17 (2023)
Abstract Background Pancreatic adenocarcinoma (PAAD) is an aggressive solid tumour characterised by few early symptoms, high mortality, and lack of effective treatment. Therefore, it is important to identify new potential therapeutic targets and prog
Externí odkaz:
https://doaj.org/article/6ee9147861b140329075238f721c7c9e
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Winfried Neuhaus
Publikováno v:
Frontiers in Molecular Neuroscience, Vol 10 (2017)
The blood-brain barrier (BBB) is damaged during ischemic insults such as traumatic brain injury or stroke. This contributes to vasogenic edema formation and deteriorate disease outcomes. Enormous efforts are pursued to understand underlying mechanism
Externí odkaz:
https://doaj.org/article/45f070c4c5d24d2f9fccae69e638f3df
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Molecules, Vol 16, Iss 12, Pp 10013-10028 (2011)
YS-121 [2-(4-chloro-6-(2,3-dimethylphenylamino)pyrimidin-2-ylthio)octanoic acid] is the result of target-oriented structural derivatization of pirinixic acid. It is a potent dual PPARα/γ-agonist, as well as a potent dual 5-LO/mPGES-1-inhibitor. Add
Externí odkaz:
https://doaj.org/article/6a51be7d690349499a98e73e5361d6fd
Autor:
Marion E. Couch, Andrea Bonetto, Joshua R. Huot, Leah J. Novinger, Thomas M. O’Connell, Fabrizio Pin, Robert A. Harris
Publikováno v:
The FASEB Journal. 33:7778-7790
Cachexia is frequently accompanied by severe metabolic derangements, although the mechanisms responsible for this debilitating condition remain unclear. Pyruvate dehydrogenase kinase (PDK)4, a critical regulator of cellular energetic metabolism, was
Autor:
Mario Wurglics, Mark N. Wass, Heiko Zettl, Manfred Schubert-Zsilavecz, Michaela Dittrich, Taravat Ghafourian, Jindrich Cinatl, Florian Rothweiler, Michael Wiese, Martin Michaelis, Natália Aniceto
Publikováno v:
Oncotarget
Pirinixic acid derivatives, a new class of drug candidates for a range of diseases, interfere with targets including PPARα, PPARγ, 5-lipoxygenase (5-LO), and microsomal prostaglandin and E2 synthase-1 (mPGES1). Since 5-LO, mPGES1, PPARα, and
Autor:
Aron H. Lichtman, Mark K. Greenwald, Pretal P. Muldoon, Asti Jackson, Deniz Bagdas, Michael F. Miles, F. Ivy Carroll, M. Imad Damaj
Publikováno v:
Neuropharmacology. 118:38-45
United States Department of Health & Human Services National Institutes of Health (NIH) - USA NIH National Institute on Drug Abuse (NIDA) - R01 DA12610 - R01 DA032246 - T32 DA007027-41 United States Department of Health & Human Services National Inst
Autor:
Daniel Merk, Julius Pollinger
Publikováno v:
Expert Opinion on Therapeutic Patents. 27:517-525
WY14643 - also known as pirinixic acid - is a versatile fatty acid mimetic that was originally developed as lipid lowering agent without knowledge of its molecular target. Various later studies discovered somewhat promiscuous activity of the compound
Autor:
Mario Wurglics, Maximilian Pohland, Maren Pellowska, Gunter P. Eckert, Stephanie Hagl, Manfred Schubert-Zsilavecz
Publikováno v:
Neurochemical Research. 41:231-242
Developing new therapeutic strategies for Alzheimer's disease (AD) is a current challenge. Approved drugs merely act symptomatically and delay the progression of the disease for a relatively short period of time. Here, we investigated the effectivene